/IBER

IBER Stock - Ibere Pharmaceuticals

Q: What is the analyst price target for IBER?

Analyst price target information is not currently available for IBER.

Q: What is IBER's market cap?

Market capitalization information is not currently available for IBER.

Financial Services|Shell Companies|NYSE

$10.18-0.29%

$0.03 (-0.29%) • Mar 1

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $11.20

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for IBER

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2021

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.00

52W High$10.75

52W Low$9.75

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2021
Revenue	N/A
Gross Profit	$-1,004,000
Gross Margin	N/A
Operating Income	$-1,004,000
Net Income	$1.56M
Net Margin	N/A
EPS	$0.34

Company Overview

Ibere Pharmaceuticals does not have significant operations. It focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Philadelphia, Pennsylvania.

Visit Website

Earnings History & Surprises

IBER

Beat Rate

Last 0 quarters

Avg Surprise

+0%

EPS vs Estimate

Beats / Misses

0/0

Last 12 quarters

Latest EPS

$0.11

Q4 2022

EPS Surprise History

Q1 21

No data

Q2 21

No data

Q3 21

No data

Q4 21

No data

Q1 22

No data

Q2 22

No data

Q4 22

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2023	Mar 6, 2023	—	—	—	—
Q4 2022	Nov 14, 2022	—	$0.11	—	—
Q2 2022	Jun 30, 2022	—	$0.18	—	—
Q1 2022	Mar 31, 2022	—	$0.43	—	—
Q4 2021	Dec 31, 2021	—	$0.07	—	—
Q3 2021	Sep 30, 2021	—	$0.10	—	—
Q2 2021	Jun 30, 2021	—	$-0.01	—	—
Q1 2021	Mar 31, 2021	—	$-0.01	—	—

Frequently Asked Questions about IBER

What is IBER's current stock price?

Ibere Pharmaceuticals (IBER) is currently trading at $10.18 per share. The stock has moved -0.29% today.

What is the analyst price target for IBER?

No analyst price targets are currently available for this stock.

What sector is Ibere Pharmaceuticals in?

Ibere Pharmaceuticals operates in the Financial Services sector, specifically within the Shell Companies industry. The company is traded on the NYSE exchange.

What is IBER's market cap?

Ibere Pharmaceuticals has a market capitalization of $0.18 billion, making it a small-cap company.

Does IBER pay dividends?

No, Ibere Pharmaceuticals does not currently pay a dividend to shareholders.